search

Active clinical trials for "Mitral Valve Insufficiency"

Results 91-100 of 367

European FIH Study - NeoChord Transcatheter Mitral Repair System for Symptomatic Mitral Regurgitation...

Mitral Valve InsufficiencyMitral Valve Prolapse5 more

Safety and performance evaluation of the NeoChord Transcatheter Mitral Repair System in patients with degenerative mitral valve regurgitation.

Not yet recruiting39 enrollment criteria

To Evaluate the Efficacy and Safety of the Transfemoral Mitral Valve Repair System in the Treatment...

Mitral Valve Insufficiency

To confirm the effectiveness and safety of the transcatheter mitral valve repair system for the treatment of chronic moderate to severe (3+) or severe (4+) functional mitral regurgitation (FMR) who remained clinically symptomatic after guideline-directed medical treatment.

Not yet recruiting37 enrollment criteria

Impact of Mitral Regurgitation on Coronary Haemodynamics and Instantaneous Effect of Transcatheter...

Mitral Valve InsufficiencyCoronary Stenosis2 more

In the present study, the investigators aim to use the in-vivo Transcatheter Mitral Valve Repair (TMVR) model to determine how Mitral Regurgitation (MR) affects coronary hemodynamics in patients affected with severe MR and concomittant angiographically-documented coronary artery disease. The investigators will also provide unique physiologic data on the acute effect of TMVR using the MitraClip system on coronary microcirculation in patients with severe MR.

Active16 enrollment criteria

Edge-to-edge Mitral Valve Repair in ATTR-CM

Mitral RegurgitationATTR-Cardiomyopathy1 more

No previous study has evaluated the effectiveness of transcatheter edge-to-edge mitral valve repair (TEER) in patients with ATTR-associated cardiomyopathy (ATTR-CM) and significant mitral regurgitation, as this specific patient population was specifically excluded from previous large TEER trials. From a pathophysiological perspective, effective treatment of significant regurgitant volume and consecutive improvement of forward volume appears highly desirable in a condition with intrinsically low output. However, whether this translates into improved functional capacity, better quality of life, and better clinical outcomes compared to conservative heart failure management alone remains to be investigated.

Not yet recruiting22 enrollment criteria

Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study

Mitral RegurgitationTricuspid Regurgitation1 more

ARB-PMCF is a multicenter, observational study of the safety and performance of Abbott annuloplasty devices used in surgical repair of mitral and tricuspid valve regurgitation. The devices included in this study are the SJM™ Rigid Saddle Ring and SJM Séguin Annuloplasty Ring, indicated for mitral valve repair, and the SJM Tailor™ Annuloplasty Ring and SJM Tailor Annuloplasty Band, indicated for mitral or tricuspid repair. Participants will be enrolled prior to undergoing mitral or tricuspid valve repair surgery including an Abbott annuloplasty implant and will complete annual follow-up visits through five years from implant. The study is being conducted to meet post-market clinical follow-up requirements of the European Union Medical Device Directives.

Recruiting13 enrollment criteria

Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation

Mitral Valve Regurgitation

To evaluate the safety and performance of the Tendyne™ Mitral Valve System when used as intended in a contemporary, real-world setting.

Recruiting7 enrollment criteria

Feasibility Study of the Tioga TMVR System

Mitral Regurgitation

The study is aimed to assess the safety and feasibility of the Tioga TMVR System in treating patients with symptomatic MR (MR>=3+)

Not yet recruiting33 enrollment criteria

Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair

Congenital Mitral Insufficiency

The goal of this observational study is to compare the safety and effectiveness of a modified drug therapy with traditional drug therapy in pediatric patients after mitral repair. The main questions it aims to answer are: Can a modified drug therapy improve both left ventricular and mitral valve function in pediatric patients after mitral repair? Can the adverse drug reactions caused by the modified drug therapy be non-inferior (clinically acceptable) to those of the traditional drug therapy? Participants will be assigned to either the Modified Drug Therapy Group (comprising angiotensin-converting enzyme inhibitor (ACE-I), beta-blockers, diuretics, potassium supplements, and spironolactone) or the Traditional Drug Therapy Group (diuretics and potassium supplements) based on personal preferences and clinical assessments by their attending physicians. They will undergo a 6-months course of medication. Additionally, echocardiography, electrocardiograms, complete blood counts, biochemical tests, and measurements of N-terminal pro-brain natriuretic peptide (NT-proBNP) were conducted before the initiation of medication therapy and at 1 month, 3 months, and 6 months after treatment commencement. Researchers will compare the Modified Drug Therapy Group and the Traditional Drug Therapy Group to see if the recurrence rate of moderate to severe mitral valve regurgitation, as assessed by echocardiography after 6 months of treatment, is lower in the former than in the latter.

Recruiting7 enrollment criteria

Aortic or Mitral Valve Replacement With the Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis...

Aortic Valve InsufficiencyAortic Valve Regurgitation6 more

Collect data on the safety and clinical performance of the Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis

Recruiting46 enrollment criteria

A Prospective, Multicenter Study to Evaluate the JensClip Transcatheter Valve Repair System

Degenerative Mitral Valve DiseaseMitral Valve Regurgitation

The clinical trial study is designed as a prospective, multicenter, single-group target value clinical study to evaluate the safety and efficacy of the clinical investigational product and to evaluate its performance using the above clinical trial primary endpoint and secondary endpoint indicators.

Not yet recruiting29 enrollment criteria
1...91011...37

Need Help? Contact our team!


We'll reach out to this number within 24 hrs